Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$49.02 USD
-0.72 (-1.45%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $49.40 +0.38 (0.78%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
BMY 49.02 -0.72(-1.45%)
Will BMY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMY
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key Facts
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
Alexandria Sells Asset to Redeploy in Development, Redevelopment Moves
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Other News for BMY
5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025
Centessa Pharmaceuticals a new buy at B Riley on sleep disorders pipeline
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis